MARKET

NXTC

NXTC

Nextcure
NASDAQ
11.10
+0.01
+0.09%
After Hours: 11.09 -0.01 -0.09% 17:50 02/06 EST
OPEN
11.30
PREV CLOSE
11.09
HIGH
11.40
LOW
11.10
VOLUME
4.38K
TURNOVER
--
52 WEEK HIGH
15.74
52 WEEK LOW
2.688
MARKET CAP
38.91M
P/E (TTM)
-0.4589
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NXTC last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at NXTC last week (0119-0123)?
Weekly Report · 01/26 10:20
NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials
Reuters · 01/26 06:55
NextCure Updates ADC Pipeline Progress and Cash Runway
TipRanks · 01/23 12:47
NextCure Inc. Highlights Targeted Cancer Therapy and Clinical Pipeline in New Presentation
Reuters · 01/23 12:11
NextCure Shares Update on Cancer Drug Trials, Cash Runway Extends Into 2027
Benzinga · 01/23 12:05
NextCure expects SIM0505 Phase 1 dose escalation data update in Q2
TipRanks · 01/23 12:05
NEXTCURE INC - EXPECTS FUNDS TO LAST INTO FIRST HALF OF 2027
Reuters · 01/23 12:00
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.